Saturday 17 October 2026
Export BBNX’s income statement to Excel — free account
Beta Bionics, Inc.
BBNX Healthcare Medical Devices
Beta Bionics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.3 million, up 53.9% from fiscal 2024. In the quarter to June 2026, revenue grew 37.8%, EPS fell 35.9% and free cash flow fell 1.87%, each against the same quarter a year earlier.
16.35
0.96
−5.55%
Follow BBNX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+7 more quarters Free account |
P/S ratio |
5.87 | 4.04 | 12.32 | 9.79 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(47.74) | (18.68) | (143.15) | (99.32) | |
P/B ratio |
2.72 | 1.64 | 4.29 | 2.94 | |
Price to Tangible BV |
2.72 | 1.64 | 4.29 | 2.94 | |
EV/Sales |
4.35 | 2.23 | 10.13 | 7.21 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.27) | (4.48) | (19.94) | (11.28) | |
EV/FCF |
(1.53) | (0.73) | (3.05) | (10.55) | |
Quick Ratio |
7.64 | 9.29 | 7.64 | 9.46 | |
Current Ratio |
8.88 | 10.69 | 8.66 | 10.64 | |
Net Debt/EBITDA |
7.44 | 8.57 | 14.43 | 15.63 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.38 | 0.34 | 0.42 | 0.40 | |
Operating CF/Net income |
0.62 | 1.09 | 0.64 | 0.61 | |
Capex/Depreciation |
(0.80) | (1.40) | (298.01) | (0.53) | |
Research and Development Expense of Revenue |
31.99% | 37.49% | 31.54% | 30.07% | |
Selling, General and Administrative Expense of Revenue |
106.96% | 109.87% | 77.63% | 87.94% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
21.92% | 19.57% | 13.40% | 16.43% | |
Graham Net Nets |
0.28 | 0.48 | 0.18 | 0.27 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(10.53%) | (15.07%) | (6.40%) | (21.99%) | |
Free Cash Flow Yield |
(48.44%) | (75.88%) | (26.96%) | (6.98%) | |
Revenue per Share |
0.72 | 0.62 | 0.79 | 0.62 | |
Operating CF per Share |
(0.33) | (0.54) | (0.21) | (0.20) | |
Capex per Share |
(0.02) | (0.03) | (6.88) | (0.03) | |
Free Cash Flow per Share |
(0.35) | (0.57) | (7.09) | (0.23) | |
Cash per Share |
4.05 | 4.49 | 5.41 | 5.24 | |
Shareholders Equity per Share |
5.76 | 6.10 | 7.10 | 6.76 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.76 | 6.10 | 7.10 | 6.76 | |
Free Cash Flow |
(15.66) | (25.21) | (287.27) | (10.01) | |
Working Capital |
205.02 | 224.80 | 236.98 | 244.64 | |
Capital Expenditures |
(1.04) | (1.38) | (278.64) | (1.28) | |
Net Current Asset Value |
195.01 | 214.81 | 226.77 | 234.74 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.05 | 8.67 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
14.72 | 12.41 | 14.56 | 7.99 | |
Average Payables |
4.39 | 2.89 | 3.93 | 2.81 | |
Average Inventory |
20.62 | 19.73 | 17.52 | 10.81 | |
Average Assets |
311.18 | 321.22 | 239.19 | 220.04 | |
Average Common Equity |
279.00 | 292.50 | 21.13 | 45.83 |
Columns are period end dates